SELLAS Life Sciences Group (NASDAQ:SLS) Trading Down 3.7% - Time to Sell?

Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) fell 3.7% on Tuesday . The stock traded as low as $2.04 and last traded at $2.09. 3,062,879 shares were traded during mid-day trading, an increase of 76% from the average session volume of 1,744,360 shares. The stock had previously closed at $2.17.

SELLAS Life Sciences Group Stock Down 2.9%

The firm's 50 day moving average is $1.76 and its two-hundred day moving average is $1.39.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.04. Equities analysts expect that SELLAS Life Sciences Group, Inc. will post -0.57 earnings per share for the current fiscal year.

Insider Activity at SELLAS Life Sciences Group

In related news, Director Jane Wasman acquired 20,000 shares of the company's stock in a transaction dated Friday, May 30th. The stock was bought at an average price of $1.69 per share, with a total value of $33,800.00. Following the purchase, the director directly owned 30,400 shares in the company, valued at $51,376. The trade was a 192.31% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 1.40% of the stock is currently owned by corporate insiders.

Institutional Trading of SELLAS Life Sciences Group

Institutional investors have recently modified their holdings of the company. Brooklyn FI LLC purchased a new position in SELLAS Life Sciences Group in the 4th quarter worth approximately $677,000. Geode Capital Management LLC boosted its holdings in SELLAS Life Sciences Group by 21.2% in the 4th quarter. Geode Capital Management LLC now owns 733,546 shares of the company's stock worth $763,000 after acquiring an additional 128,355 shares during the period. Northern Trust Corp boosted its holdings in SELLAS Life Sciences Group by 33.6% in the 4th quarter. Northern Trust Corp now owns 134,721 shares of the company's stock worth $140,000 after acquiring an additional 33,878 shares during the period. Anson Funds Management LP boosted its holdings in SELLAS Life Sciences Group by 50.2% in the 4th quarter. Anson Funds Management LP now owns 1,192,266 shares of the company's stock worth $1,240,000 after acquiring an additional 398,431 shares during the period. Finally, Virtu Financial LLC raised its position in shares of SELLAS Life Sciences Group by 30.9% in the 1st quarter. Virtu Financial LLC now owns 53,861 shares of the company's stock valued at $58,000 after purchasing an additional 12,706 shares in the last quarter. Hedge funds and other institutional investors own 17.38% of the company's stock.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.